CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
298.31MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.77xvs all stocks
52-Week Change
-17.86%vs all stocks
Market Capitalization
298.31MUSDvs all stocks (USD)
Enterprise Value
204.61MUSDvs all stocks (USD)
Forward P/E
-2.18xvs Biotechnology peers
Price to Book (MRQ)
4.15xvs Biotechnology peers
Enterprise to EBITDA
-0.9380xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-66.39%vs Biotechnology peers
Return on Equity (TTM)
-148.74%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-218.02MUSDvs all stocks (USD)
Net Income (TTM)
-222.39MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-193.40MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-108.30MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-241.16MUSDvs all stocks (USD)
Pre-tax Income
-236.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
130.00KUSDFY2025 · Dec 31, 2025Net Income
-236.93MUSDFY2025 · Dec 31, 2025EBIT
-233.58MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-233.37MUSDFY2025 · Dec 31, 2025Research & Development
181.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
60.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.34MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
3.22MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.45USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.45USDFY2025 · Dec 31, 2025Basic Shares Outstanding
163.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
163.39MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-236.93MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-205.57MUSDFY2025 · Dec 31, 2025Free Cash Flow
-205.79MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
182.53MUSDFY2025 · Dec 31, 2025Income Tax Paid
323.00KUSDFY2025 · Dec 31, 2025Interest Paid
1.50MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-236.93MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
208.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
29.88MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.13MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
71.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.93MUSDFY2025 · Dec 31, 2025Capital Expenditures
218.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-82.87MUSDFY2025 · Dec 31, 2025Sale of Investments
251.17MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
168.52MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
57.16MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
76.81MUSDFY2025 · Dec 31, 2025Shares Outstanding
182.16MSharesUpdated Jul 19, 2026Float Shares
113.85MSharesUpdated Jul 19, 2026Shares Short
6.68MSharesUpdated Jul 19, 2026Short Ratio
1.63daysvs all stocks
Short % of Shares Outstanding
6.23%vs all stocks
% Held by Insiders
23.60%vs all stocks
% Held by Institutions
57.88%vs all stocks
Total Cash (MRQ)
147.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7940USDUpdated Jul 19, 2026Total Debt (MRQ)
53.37MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7551xvs Biotechnology peers
Current Ratio (MRQ)
5.09xvs Biotechnology peers
Book Value per Share (MRQ)
0.3880USDUpdated Jul 19, 2026Total Assets
191.05MUSDvs all stocks (USD)
Total Current Assets
190.54MUSDFY2025 · Dec 31, 2025Total Liabilities
87.18MUSDFY2025 · Dec 31, 2025Total Non-current Assets
510.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
54.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
32.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
182.53MUSDFY2025 · Dec 31, 2025Other Short-term Investments
0.00USDFY2025 · Dec 31, 2025Accounts Payable
3.38MUSDFY2025 · Dec 31, 2025Short-term Debt
284.00KUSDFY2025 · Dec 31, 2025Long-term Debt
54.73MUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.18BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
103.87MUSDvs all stocks (USD)
52-Week Low
0.8300USDUpdated Jul 19, 202652-Week High
3.65USDUpdated Jul 19, 202652-Week Change
-17.86%vs all stocks
Beta
2.77xvs all stocks
50-Day MA
1.70USDUpdated Jul 19, 2026200-Day MA
2.19USDUpdated Jul 19, 2026Avg 10-Day Volume
1.01MSharesUpdated Jul 19, 2026Avg 30-Day Volume
3.20MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.33USDUpdated Jul 19, 2026Other Income / Expense
-767.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Anhui Huangshan Capsule Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tomocube Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Immuneering Corporation
Tier 1ProductionApproval-Gated PipelineRule
908 Devices Inc.
Tier 1ProductionApproval-Gated PipelineRule
JBM
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hikal Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Essex Bio-Technology Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Foghorn Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Hunan Yujing Machinery Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline
Shanghai Fudan Microelectronics Group Co., Ltd.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedPartial Recovery After Sharp Decline